AI Article Synopsis
- This clinical guideline outlines strategies for preventing chemotherapy-induced nausea and vomiting (CINV) in children, focusing on both acute and delayed phases.
- Recommendations are based on systematic reviews of randomized controlled trials that assess different interventions for effective prevention.
- The guideline highlights specific recommendations for patients with varying levels of chemotherapy-induced nausea risks and notes areas where more research is needed regarding the safety and dosing of antiemetics.
Article Abstract
This clinical practice guideline provides recommendations for preventing acute and delayed phase chemotherapy-induced nausea and vomiting (CINV) in pediatric patients. The recommendations are based on two systematic reviews of randomized controlled trials evaluating interventions to prevent (1) acute phase CINV and (2) delayed phase CINV. Recommendations for acute phase and delayed phase CINV prophylaxis are made for patients receiving chemotherapy of varying emetogenicity, as well as for patients not able to receive dexamethasone or a neurokinin-1 receptor antagonist. Evidence gaps, including antiemetic safety and optimal dosing, were identified.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.30001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!